Drug discovery and development
We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.
LONDON, UK, 6 October 2026 – Cancer Research UK have signed an agreement with ORIC Pharmaceuticals, Inc. to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.
Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design and execute a Phase 1/2 clinical trial of ORIC-259, including CTA-enabling studies, for patients with cancer. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with Cancer Research UK eligible to receive downstream milestone payments and royalties. Cancer Research Horizons, Cancer Research UK’s innovation arm, will manage the commercial relationship between Cancer Research UK and ORIC.
ORIC-259 is a splice-modifier directed against CIP2A, a cancer-driving protein that has traditionally been considered undruggable. CIP2A plays multiple roles in cancer progression and is associated with tumour growth and survival across numerous cancer types, making it an attractive target for the development of potential new cancer treatments.
The collaboration aims to accelerate the clinical development of ORIC-259 and evaluate its potential as a new treatment option for patients with cancer. The Phase 1/2 trial will assess the safety, tolerability and preliminary anti-tumour activity of the molecule, generating important data to determine whether targeting CIP2A could offer a new therapeutic approach across a range of tumour types.
A potential area of application is in BRCA-mutant cancers, where research has identified CIP2A as a synthetic lethal vulnerability. PARP inhibitors have significantly improved outcomes for patients with these cancers, but treatment resistance remains a considerable clinical challenge. Because CIP2A targeting has a distinct mechanism from PARP, ORIC-259 could offer a new approach for patients whose cancers have become resistant to PARP inhibitors, while also creating opportunities to combine CIP2A-targeted therapies with PARP inhibitors or other agents.
This programme builds on Cancer Research UK and the UK’s pioneering role in PARP inhibitor development, drawing on deep expertise in translating synthetic lethal approaches into treatments for patients with BRCA-mutant and HRD cancers.
Lars Erwig, Director of the CDD, said: “ORIC-259 represents an innovative approach to targeting CIP2A, a protein with significant potential in cancer but one that has proven difficult to drug. We share ORIC’s mission to overcome treatment resistance in cancer, and we look forward to applying our expertise to explore new treatment options for patients.”
Lori Friedman, Chief Scientific Officer of ORIC, said: “We are excited to partner with Cancer Research UK to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into the clinic. Cancer Research UK’s proven expertise and capabilities in developing innovative cancer therapies make it an ideal partner for the program, while this structure allows us to remain disciplined in allocating our internal resources to our late-stage clinical pipeline.”
ENDS
About Cancer Research UK's Centre for Drug Development
Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 30 years. It has completed over 170 clinical trials designed to explore potential new anti-cancer agents in patients. Six of these new agents have made it to market, including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. www.cruk.org.uk/cdd
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow on X or LinkedIn.
ORIC and the stylised ORIC mark are registered trademarks of ORIC Pharmaceuticals, Inc.
Contact
Tim Bodicoat
Content Manager, Cancer Research UK
[email protected]
